MedPath

Carbetocin versus oxytocin for the prevention of post-partum hemorrhage in caesarean sectio

Phase 4
Completed
Conditions
Pregnancy and Childbirth
Third stage of labour
Registration Number
ISRCTN69805695
Lead Sponsor
Beacon Pharmaceuticals Ltd (Bangladesh)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
64
Inclusion Criteria

Women with a single pregnancy undergoing cesarean delivery at term

Exclusion Criteria

1. Placenta praevia
2. Multiple gestations
3. Placental abruption
4. Hypertensive disorders in pregnancy
5. Preeclampsia
6. Cardiac, renal or liver diseases
7. Epilepsy
8. Women with history of hypersensitivity to carbetocin according to the Br National Formulary

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy of carbetocin over oxytocin for the management of third stage of labor
Secondary Outcome Measures
NameTimeMethod
1. The need for additional uterotonic within 24 hours of delivery after carbetocin or oxytocin administration <br>2. The amount of blood loss in 24 hours after delivery after carbetocin or oxytocin administration<br>3. The need for blood transfusion during the first 24 hours after delivery after carbetocin or oxytocin administration<br>4. The adverse effects of carbetocin and oxytocin after administration
© Copyright 2025. All Rights Reserved by MedPath